TherapeuticsMD Company Insiders
| TXMD Stock | USD 2.25 0.03 1.32% |
TherapeuticsMD's insiders are aggressively buying. The analysis of insiders' sentiment of trading TherapeuticsMD stock suggests that all insiders are extremely bullish at this time. TherapeuticsMD employs about 1 people. The company is managed by 14 executives with a total tenure of roughly 35 years, averaging almost 2.0 years of service per executive, having 0.07 employees per reported executive.
| Robert Finizio CEO Co-Founder, CEO and Director |
| Michael Donegan President Vice President - Finance |
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-12-23 | Tommy G Thompson | Acquired 8400 @ 1.67 | View | ||
| 2025-04-14 | Tommy G Thompson | Acquired 325 @ 1 | View | ||
| 2025-04-09 | Marlan D Walker | Acquired 1136 @ 0.87 | View |
Monitoring TherapeuticsMD's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
TherapeuticsMD | Build AI portfolio with TherapeuticsMD Stock |
TherapeuticsMD's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with TherapeuticsMD's future performance. Based on our forecasts, it is anticipated that TherapeuticsMD will maintain a workforce of about 5 employees by March 2026.TherapeuticsMD Management Team Effectiveness
The company has return on total asset (ROA) of (0.0273) % which means that it has lost $0.0273 on every $100 spent on assets. This is way below average. TherapeuticsMD's management efficiency ratios could be used to measure how well TherapeuticsMD manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2026, Return On Tangible Assets is expected to decline to -0.08. In addition to that, Return On Capital Employed is expected to decline to -0.17. At present, TherapeuticsMD's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.8 M, whereas Other Current Assets are forecasted to decline to about 1.4 M.The current year's Common Stock Shares Outstanding is expected to grow to about 13.9 M, whereas Net Loss is projected to grow to (147.4 M). The market capitalization of TherapeuticsMD is $26.04 Million. About 69.21 % of TherapeuticsMD outstanding shares are held by general public with 1.54 (%) owned by insiders and only 29.25 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Shares in Circulation | First Issued 1999-03-31 | Previous Quarter 11.6 M | Current Value 11.6 M | Avarage Shares Outstanding 6.3 M | Quarterly Volatility 15.9 M |
TherapeuticsMD Workforce Comparison
TherapeuticsMD is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 393,450. TherapeuticsMD adds roughly 1.0 in number of employees claiming only tiny portion of equities under Health Care industry.
TherapeuticsMD Profit Margins
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.38) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.38.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.93 | 0.88 |
|
|
TherapeuticsMD Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TherapeuticsMD insiders, such as employees or executives, is commonly permitted as long as it does not rely on TherapeuticsMD's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, TherapeuticsMD insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 1.1667 | 7 | 6 | 33,781 | 31,470 |
| 2023-12-01 | 0.6667 | 2 | 3 | 947,192 | 89,050 |
| 2023-06-01 | 0.8889 | 8 | 9 | 372,777 | 62,114 |
| 2023-03-01 | 1.5 | 9 | 6 | 130,305 | 6,546 |
| 2022-12-01 | 0.7647 | 13 | 17 | 53,169 | 76,506 |
| 2022-09-01 | 2.0 | 22 | 11 | 788,323 | 37,594 |
| 2022-03-01 | 10.0 | 10 | 1 | 6,020,000 | 230,000 |
| 2021-12-01 | 2.5 | 5 | 2 | 2,035,000 | 144,790 |
| 2021-09-01 | 2.1667 | 39 | 18 | 13,704,685 | 1,818,848 |
| 2021-06-01 | 0.5833 | 7 | 12 | 543,334 | 765,221 |
| 2021-03-01 | 0.2857 | 2 | 7 | 358,000 | 1,044,428 |
| 2020-06-01 | 23.0 | 23 | 1 | 2,764,908 | 434,814 |
| 2020-03-01 | 3.5 | 14 | 4 | 3,541,000 | 900,000 |
| 2018-12-01 | 0.2979 | 28 | 94 | 2,795,385 | 9,465,880 |
| 2018-09-01 | 0.5862 | 17 | 29 | 1,605,614 | 3,402,014 |
| 2018-03-01 | 6.0 | 6 | 1 | 1,320,000 | 25,000 |
| 2017-12-01 | 1.0 | 1 | 1 | 5,000 | 0.00 |
| 2017-09-01 | 1.0 | 1 | 1 | 5,000 | 150,000 |
| 2016-06-01 | 2.0 | 2 | 1 | 122,744 | 100,000 |
| 2015-12-01 | 7.0 | 14 | 2 | 2,775,000 | 0.00 |
| 2015-09-01 | 3.0 | 3 | 1 | 23,843 | 50,000 |
| 2015-06-01 | 1.6 | 8 | 5 | 147,000 | 240,000 |
| 2014-12-01 | 0.375 | 3 | 8 | 190,000 | 295,000 |
| 2014-06-01 | 2.2 | 11 | 5 | 412,052 | 310,000 |
| 2014-03-01 | 0.1803 | 11 | 61 | 457,500 | 11,534,741 |
| 2013-12-01 | 1.0 | 1 | 1 | 250,000 | 0.00 |
| 2013-09-01 | 5.0 | 5 | 1 | 135,728 | 1,600,000 |
| 2013-06-01 | 4.0 | 8 | 2 | 575,000 | 2,631,579 |
| 2012-03-01 | 0.4 | 2 | 5 | 600,000 | 92,057 |
| 2011-12-01 | 0.6667 | 4 | 6 | 1,800,000 | 296,628 |
| 2005-09-01 | 0.6 | 3 | 5 | 112,117 | 39,063 |
| 2005-03-01 | 1.5 | 3 | 2 | 2,500 | 2,000 |
| 2004-12-01 | 2.0 | 2 | 1 | 2,000 | 0.00 |
TherapeuticsMD Notable Stakeholders
A TherapeuticsMD stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as TherapeuticsMD often face trade-offs trying to please all of them. TherapeuticsMD's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting TherapeuticsMD's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Finizio | Co-Founder, CEO and Director | Profile | |
| Governor Thompson | Executive Chairman | Profile | |
| Michael Donegan | Vice President - Finance | Profile | |
| Mitchell Krassan | Executive VP and Chief Strategy Performance Officer | Profile | |
| Hugh MBA | Pres Director | Profile | |
| MD FACOG | CoFounder,CoCEO Officer | Profile | |
| Douglas Steelman | Vice Access | Profile | |
| Benjamin Foulk | Vice Resources | Profile | |
| Dedra Lyden | Vice Initiatives | Profile | |
| Joseph Ziegler | Principal Officer | Profile | |
| Daniella Silva | Chief Officer | Profile | |
| Mark Glickman | CoCEO Officer | Profile | |
| Marlan JD | Chief Officer | Profile | |
| Bharat Warrier | Chief Officer | Profile |
About TherapeuticsMD Management Performance
The success or failure of an entity such as TherapeuticsMD often depends on how effective the management is. TherapeuticsMD management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of TherapeuticsMD management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the TherapeuticsMD management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.08) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.06) | (0.07) | |
| Return On Equity | (0.09) | (0.09) |
Please note, the presentation of TherapeuticsMD's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, TherapeuticsMD's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of TherapeuticsMD's management manipulating its earnings.
TherapeuticsMD Workforce Analysis
Traditionally, organizations such as TherapeuticsMD use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare TherapeuticsMD within its industry.TherapeuticsMD Manpower Efficiency
Return on TherapeuticsMD Manpower
| Revenue Per Employee | 1.8M | |
| Revenue Per Executive | 125.8K | |
| Net Loss Per Employee | 2.3M | |
| Net Loss Per Executive | 165.1K | |
| Working Capital Per Employee | 7.1M | |
| Working Capital Per Executive | 506.6K |
Complementary Tools for TherapeuticsMD Stock analysis
When running TherapeuticsMD's price analysis, check to measure TherapeuticsMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TherapeuticsMD is operating at the current time. Most of TherapeuticsMD's value examination focuses on studying past and present price action to predict the probability of TherapeuticsMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TherapeuticsMD's price. Additionally, you may evaluate how the addition of TherapeuticsMD to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |